ClinicalTrials.gg
RecruitingNCT06911372Updated Dec 16, 2025

The Impact of Gestational Diabetes Mellitus on Cerebral Blood Flow and Cerebrovascular Function After Pregnancy

A Phase 1 interventional study of Intradermal Microdialysis and Brain Blood Flow Tests in Gestational Diabetes Mellitus (GDM), Postpartum Women and Uncomplicated Pregnancy, sponsored by Anna Stanhewicz, PhD. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-16.

Sponsored by Anna Stanhewicz, PhD · Phase 1, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
84
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 251 studies in Diabetes, Gestational with a site in United States — 52 open to participants now, 65 under way, 2 of them phase 3. Diabetes, Gestational · United States.

Planned enrollment
94th of 194
84 · median 80
Started
2025
with 24 others
Phase 1
11 of 251
5 open now
Primary completion
2027-04
later than 39 of 64 live
Registered
229th of 251
by date
Lead sponsor
5 of 251
Anna Stanhewicz, PhD

Among the 251 studies in Diabetes, Gestational with a site in United States, this one is the 94th largest by planned enrollment of the 194 interventional ones that give a count, is one of 25 that started in 2025, is one of 11 in phase 1, reaches primary completion later than 39 of the 64 other live ones, and was the 229th registered.

Diabetes, Gestational

878 studies on the registry are indexed under Diabetes, Gestational; 196 are open to participants now.

Browse Diabetes, Gestational studies →

Open to participants now

52 of the 251 studies in Diabetes, Gestational with a site in United States are open now. Recruiting first, the newest first:

46 more — sign in →

All 52 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 132 Diabetes, Gestational studies recruiting now, 60 (45%) set no upper age limit and 70 (53%) stop at 75 or younger; 12 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 50 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 251 studies in Diabetes, Gestational with a site in United States, or all of them as a file.
02

Study summary

Gestational Diabetes Mellitus (GDM) currently affects approximately 14% of all pregnancies worldwide. Importantly, the health-related consequences of GDM extend well beyond pregnancy, such that women with a history of GDM have a 40% increased risk of cerebrovascular diseases and a 67% increased risk of dementia, compared to women with a history of uncomplicated pregnancy. Women with a history of GDM have impaired skin microvascular function, compared with women with a history of uncomplicated pregnancy. Therefore, it's likely that GDM results in impaired brain blood vessel function, yet there is little-to-no information regarding the effects of GDM on brain blood vessel health and function after pregnancy.

Therefore, the purpose of the study is to evaluate the effects of GDM on brain blood flow and brain blood vessel function in healthy women with either a history of GDM or uncomplicated pregnancy.

In this study, the investigators will use two different types of ultrasound to non-invasively measure brain blood flow. Brain blood vessel function will be evaluated by examining the brain blood flow responses to increases in carbon dioxide (the increases in carbon dioxide are similar to what is experienced during a breath hold). Additionally, the investigators will compare the brain blood flow results to skin microvascular function to explore potential mechanisms behind possible impairments in brain blood vessel function. Skin microvascular function will be assessed using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents) on dime sized areas of the forearm. Finally, for screening purposes and to further explore potential mechanisms behind any potential impairments in brain blood vessel function, the investigators will perform blood draws to determine the metabolic health of the participants and to analyze for substances that influence blood vessel function.

03

Conditions studied

  • Gestational Diabetes Mellitus (GDM)
  • Postpartum Women
  • Uncomplicated Pregnancy

Browse trials for

Keywords

  • Gestational Diabetes
  • Brain Blood Flow
  • Pregnancy
  • Postpartum
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Eligibility criteria

INCLUSION CRITERIA:

  • Post-partum women
  • 18 years or older
  • Delivered within 5 years from the study visit
  • History of gestational diabetes diagnosed by an obstetrician and confirmed according to the American College of Obstetricians and Gynecologists criteria for gestational diabetes OR history of uncomplicated pregnancy (defined as no history of gestational diabetes, hypertensive pregnancy, or other gestational disorder).

EXCLUSION CRITERIA: We exclude participants from both groups for:

  • Skin diseases
  • Current tobacco use
  • Diagnosed or suspected hepatic or metabolic disease including diabetes
  • Diagnosed with depression or other mood-related disorders, asthma, , cystic fibrosis, or pulmonary fibrosis
  • Use of prescribed NSAIDs, statins or other cholesterol-lowering medication, antihypertensive medication, carbonic anhydrase inhibitors, , thyroid medications, antidepressants or mood stabilizers, diuretics, phenothiazines, or benzodiazepines
  • History of preeclampsia or gestational hypertension,
  • History or family history of panic disorder,
  • Currently pregnant
  • \<18.5 kg/m2,
  • Allergy to materials used during the experiment (e.g. latex), known allergies to study drugs.
  • History of heavy alcohol use/binge drinking,
  • Have planned procedures with radiological contrast,
  • Have a major dental procedure/surgery coming up, such as a dental extraction
  • Anatomy of the middle cerebral artery or internal carotid artery that prevents adequate ultrasonography and/or and data collection
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    Vascular Tests

    All women will complete the same protocol, regardless of pregnancy history.

    Drug: Intradermal Microdialysis · Other: Brain Blood Flow Tests · Other: Local Heating

Interventions

  • DrugIntradermal Microdialysis

    A total of three microdialysis sites will be perfused with ringer's solution, L-NAME, or ketorolac (one drug per site). After a baseline period, all three sites will undergo tests of blood vessel function including an acetylcholine dose-response protocol and a test of maximal skin blood flow with sodium nitroprusside.

  • OtherBrain Blood Flow Tests

    Participants will complete CO2 breathing procedures to evaluate brain blood vessel health.

  • OtherLocal Heating

    A dime-sized heater will be placed on the skin to evaluate cutaneous microvascular function

06

What researchers measure

Primary outcomes

  1. Stepped hypercapnia-induced change in middle cerebral artery velocity

    Middle cerebral artery velocity responses to stepped concentrations of inhaled carbon dioxide gas

    Time frame: During the study visit, an average of 5 hours

  2. Hypercapnia-induced change in internal carotid artery diameter

    Internal carotid artery shear-mediated dilation response to inhaled carbon dioxide

    Time frame: During the study visit, an average of 5 hours

  3. Change in microvascular blood flow response to increasing concentrations of acetylcholine

    Cutaneous vascular vasodilator responses to acetylcholine perfusion in lactated Ringer's, ketorolac, and L-NAME treated microdialysis sites.

    Time frame: During the study visit, an average of 5 hours

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2025 (actual). Primary completion is estimated for Apr 2027, 19 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2025
First posted
Apr 4, 2025
StartActual
Aug 22, 2025
Primary completionEst.
Apr 15, 2027
CompletionEst.
Apr 15, 2028
Last update
Dec 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06911372
Lead sponsor
Anna Stanhewicz, PhD
Responsible party
Anna Stanhewicz, PhD (Assistant Professor, University of Iowa) — Sponsor-investigator
First posted
Apr 4, 2025
Start date
Aug 22, 2025
Primary completion
Apr 15, 2027 (estimated)
Completion
Apr 15, 2028 (estimated)
Last update
Dec 16, 2025

Study contacts

Anna Reid-Stanhewicz, PHD
Contact
anna-stanhewicz@uiowa.edu
319-467-1732

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion